IJGC Podcast

By BMJ GroupMedicine Health & Fitness

IJGC Podcast episodes

September 09, 2022 ATHENA-MONO Trial with Bradley J. Monk
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Professor Bradley J. Monk to discuss the ATHENA-MONO clinical trial. Prof. Monk is an international thought leader and clinical trialist who has developed and advocated for maintenance treatment in newly diagnosed advanced and recurrent ovarian cancer. ATHENA-MONO represents his fifth positive randomized phase 3 trial studying maintenance treatment and adds confidence to this efficacious and tolerable paradigm changing opportunity for all patients regardless of the molecular genotype (allcomers).
Highlights:
- Maintenance therapy is now the global standard of care in patients with advanced or recurrent epithelial ovarian cancer. This can include a PAPP inhibitor, bevacizumab, or the combination.
- Maintenance treatment is efficacious in all molecular subgroups and is tolerable without an impairment in the quality of life.
- Payers acknowledge the value of maintenance treatment as do consensus guidelines.
44 min
September 06, 2022 SLN Mapping in Endometrial Hyperplasia with Devon Abt
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Devon Abt to discuss SLN mapping in endometrial hyperplasia. Devon is a fourth-year Resident in Obstetrics & Gynecology at Beth Israel Deaconess Medical Center/Harvard Medical School currently applying into Gynecologic Oncology fellowship.
Highlights:
- Fewer than 30% of patients with preoperative diagnosis of endometrial intraepithelial neoplasia had concurrent endometrial cancer on final pathology.
Endometrial stripe ≥20mm was associated with 2 times the risk of concurrent endometrial cancer.
- Routine SLND in all patients with preoperative diagnosis of endometrial intraepithelial neoplasia is not cost-effective and would result in overtreatment.
- Endometrial stripe may be a criterion for selectively using a sentinel lymph node algorithm in patients with preoperative diagnosis of endometrial intraepithelial neoplasia who are poor candidates for lymphadenectomy or at institutions where frozen section is not available or reliable.
29 min
August 11, 2022 IJGC EiC Summer Podcasts: Parp Inhibitors: Treatment and Adverse Events with Ainhoa Madariaga
In this rebroadcasted episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Ainhoa Madariaga to discuss parp inhibitor treatments and adverse events. Dr. Madariaga's article "Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events" (ijgc.bmj.com/content/early/2020…8/ijgc-2020-001288), was the Lead Article in the July 2020 issue of IJGC. Dr. Madariaga is a medical oncologist working as a clinical research fellow in the gynecology and drug development program at Princess Margaret Cancer Centre. Her clinical and academic areas of interest are gynecologic cancers and early phase clinical trial design, such as development of drug-repurposing studies, cancer treatment adverse event and patient reported outcomes assessment.
Original release date: July 6, 2021
26 min
August 11, 2022 IJGC EiC Summer Podcasts: ESGO-ESTRO-ESP Endometrial Cancer Guidelines with Nicole Concin
In this rebroadcasted episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Nicole Concin to discuss the ESGO-ESTRO-ESP Endometrial Cancer Guidelines.
Original release date: January 4, 2021
44 min
August 11, 2022 IJGC EiC Summer Podcasts: Updates on Role of HIPEC in Ovarian Cancer with Oliver Zivanovic
In this rebroadcasted episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Oliver Zivanovic to discuss updates on role of HIPEC in ovarian cancer. Dr. Zivanovic is a Gynecologic Cancer Surgeon at Memorial Sloan Kettering Cancer Center, with the goal to advance the early detection and treatment of women with gynecologic cancers. His special interests include the treatment of patients with advanced stage ovarian cancer and electronic patient-reported symptom monitoring after cancer surgery.
Original release date: August 30, 2021
48 min
August 02, 2022 IJGC EiC Summer Podcasts: ConCerv Trial with Kathleen Schmeler
In this rebroadcasted episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Kathleen Schmeler to discuss the ConCerv Trial. Dr. Schmeler is the lead author of “ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer,” which was the Lead Article of IJGC’s October 2021 issue. Dr. Schmeler is a Professor in Gynecologic Oncology at The University of Texas MD Anderson Cancer Center. She provides care to women with gynecologic malignancies including surgery, chemotherapy and preventive services. Dr. Schmeler is also the Executive Director of Global Oncology for the MD Anderson Cancer Network. Her research interest is in cervical cancer prevention and treatment, particularly for resource-constrained countries and medically underserved communities in the US.
Original release date: October 4, 2021
Highlights:
- The ConCerv trial is the first prospective study of conservative surgery in women with low-risk cervical cancer. It included 14 sites in 9 countries.
- Findings from the ConCerv Trial offer prospective data supporting a more conservative approach to low-risk patients, sparing them the early and late morbidity associated with radical procedures.
- It will also allow for safer cervical cancer surgery in low- and middle-income countries, where the burden of cervical cancer is highest.
- In our study, conservative surgery was associated with a 3.5% recurrence rate in women with low-risk cervical cancer. In addition, the rate of positive lymph nodes was 5%, with lymph node assessment recommended in this low-risk population.
- Further study is needed to determine long term outcomes and optimal pathologic criteria for conservative surgery.
49 min
July 27, 2022 Chemotherapy Response Score in Ovarian Cancer with Alejandra Martinez
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Professor Alejandra Martinez to discuss the Chemotherapy Response Score (CRS) in ovarian cancer. Prof. Martinez has been the Deputy Head of the Surgical Oncology Department at Toulouse University Cancer Center (Institut Universitaire du Cancer de Toulouse) since 2016. She has served as the Director of the ESGO fellowship program of the IUCTO since 2017 and as a professor in oncology since 2021.
Highlights:
- CRS is an easy and reproductible biomarker that can help to stratify a patient's treatment.
- CRS 1-2 is associated with higher tumor load, more extensive surgical procedures, residual tumor after cytoreduction, and early relapse.
- Pathology response measured by the CRS is associated with disease-free and overall survival in patients with stage IIIC/IV treated with neoadjuvant chemotherapy irrespective of the number of cycles.
33 min
July 22, 2022 Updates on Overall Survival PARP Inhibitors
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Robert Coleman and Shannon Westin to discuss updates on overall survival PARP inhibitors. Robert L. Coleman, MD, is a gynecologic oncologist is Houston Texas and serves as SVP and Chief Scientific Officer for US Oncology Research. His primary research interests are in drug development for gynecological cancers and clinical trial management; he has authored more than 350 peer-reviewed publications. Dr. Shannon Westin focuses on developmental therapeutics and the use of biomarkers to predict response and recurrence in gynecologic malignancies. She currently serves as the Director of Early Drug Development and Phase I trials in her department and is a Co-Director of the Ovarian Cancer Moonshot. She is currently the PI or co-PI for greater than 30 novel treatment trials in gynecologic malignancies.
36 min
July 18, 2022 Opportunistic Salpingectomy to Prevent Ovarian Cancer with Dr. Gillian Hanley
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Gillian Hanley to discuss opportunistic salpingectomy for the prevention of ovarian cancer. Gillian Hanley, PhD, is an Associate Professor in the department of Obstetrics & Gynaecology at the University of British Columbia and a Canada Research Chair in Population-based Gynecologic and Perinatal outcomes. She does health services research in gynecology, primarily in the area of ovarian cancer prevention.
Highlights:
1. Opportunistic salpingectomy, the removal of fallopian tubes during a hysterectomy with ovarian preservation or instead of tubal ligation, has been recommended as ovarian cancer prevention following evidence that the fallopian tube is the tissue of origin for most high grade serous ovarian cancers.
2. We recently published the first data comparing observed to expected numbers of serous and epithelial ovarian cancers following opportunistic salpingectomy done for the purposes of ovarian cancer prevention in British Columbia, Canada.
3.Our data strongly suggest that opportunistic salpingectomy is effective in preventing serous ovarian cancers. There were 0 serous cancers in the opportunistic salpingectomy, and if they had been arising at the same rate as in the control groups (hysterectomy alone and tubal ligation), we would have expected 5.3. 0 is below the low end of the 95% confidence interval.
42 min
July 11, 2022 Reviewing the June issue with Katherine Hicks-Courant and Christina Uwins
In this episode of the IJGC Podcast, Editorial Fellows Katherine Hicks-Courant and Christina Uwins discuss the contents of the June issue of IJGC.
17 min

About IJGC Podcast

From the publisher's feed

The International Journal of Gynecological Cancer (IJGC) podcast explores the latest research on detection, prevention, diagnosis, and treatment of gynecologic malignancies. Enjoy interviews with leading experts as they discuss novel and relevant topics in the field of gynecologic cancer.